RCM
ADPT icon

Raleigh Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Raleigh Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$7 – 961
2023
Q2 		$7 Sell
1
-288
-100% -$2.14K ﹤0.01% 835
2023
Q1 		$2.55K Buy
289
+43
+17% +$379 ﹤0.01% 742
2022
Q4 		$1.88K Buy
246
+63
+34% +$490 ﹤0.01% 692
2022
Q3 		$1K Buy
+183
New +$1.72K ﹤0.01% 704

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Raleigh Capital Management's ADPT Position: Q3 2023 in Review

Raleigh Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2023, closing a stake of 1 share — an estimated $7 sold.

Raleigh Capital Management first reported a position in ADPT in Q3 2022 and held it in 4 quarters. The position peaked at $2.55K in Q1 2023. 190 funds tracked by Wall St. Rank hold ADPT as of Q3 2023.

  • Raleigh Capital Management reported no remaining Adaptive Biotechnologies position as of Q3 2023 after selling out during the quarter.
  • Raleigh Capital Management sold 1 Adaptive Biotechnologies share in Q3 2023, an estimated $7.
  • Raleigh Capital Management first reported a position in Adaptive Biotechnologies in Q3 2022 and held it in 4 quarters.
  • Raleigh Capital Management's Adaptive Biotechnologies position peaked at $2.55K in Q1 2023.
  • 190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2023.

Based on Raleigh Capital Management's 13F filing for Q3 2023, filed 6 Dec 2023.